IOIsao Oze

Isao Oze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isao Oze has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.

    by Go Makimoto, Toshio Kubo, Yuka Kato, Takashi Ninomiya, Isao Oze, Kadoaki Ohashi, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Nagio Takigawa, et al.

    10100 Background: Mediastinal lymph node metastasis is associated with a poor prognosis in non-small cell lung cancer (NSCLC). The standard treatment for unresectable stage III NSCLC is concurrent chemoradiotherapy (CRT). Institutions worldwide have experienced good overall survival with surgical resection after induction CRT. Our institute reported the long-term outcome of induction CRT followed by surgery for NSCLC. The 3- and 7-year overall survival (OS) rates were 72.7 and 63.6%, respectively, both much longer than for CRT alone. Nevertheless, patients treated with CRT for NSCLC remain at risk of developing a second primary cancer (SPC). This study assessed the incidence of SPC in survivors with locally advanced NSCLC after CRT followed by surgical resection. Methods: Between October 1997 and October 2013, 112 NSCLC patients were treated with tri-modal therapy in our hospital. The main regimen consisted of docetaxel and cisplatin plus concurrent radiation at a dose of 40–46 Gy followed by surgery after 4–6 weeks. We searched for SPC using our medical record database. Results: The median patient age was 61 [range 31–78] years, with 71% stage IIIA and 29% stage IIIB. The median follow-up time was 4.5 [range 0.38–16.6] years. The 5-year overall survival rate was 71.8% and the median survival time was 13.0 years (95% confidence interval 9.7–). SPC developed in 10 of the 112 patients 0.60–15.0 years (median 5.49) after the initiation of CRT. The SPC lesions involved the lungs, stomach, and colon in two patients each and esophagus, urinary bladder, thyroid, and sarcoma in one case each. Among these 10 cases, three cases occurred inside the original radiation field. Eight patients are alive now after treating these cancers. Conclusions: The observed incidence of SPC was 1.8 per 100 patient-years (95% CI 1.6–2.1) and was slightly lower than our previously reported value of 2.4 per 100 patient-years for patients treated with CRT alone (total radiation dose ≥ 60 Gy). The reduction in RT dose by adding surgery may decrease the incidence of SPC. NSCLC patients need to be followed carefully for the long-term to avoid overlooking SPC.

  • Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703

    by Kenichiro Kudo, Katsuyuki Hotta, Eiki Ichihara, Hiroshige Yoshioka, Kei Kunimasa, Kazuya Tsubouchi, Masahiro Iwasaku, Yuka Kato, Isao Oze, Nagio Takigawa, et al.